CN113917016A - Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology - Google Patents
Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology Download PDFInfo
- Publication number
- CN113917016A CN113917016A CN202111163684.3A CN202111163684A CN113917016A CN 113917016 A CN113917016 A CN 113917016A CN 202111163684 A CN202111163684 A CN 202111163684A CN 113917016 A CN113917016 A CN 113917016A
- Authority
- CN
- China
- Prior art keywords
- acid
- mass spectrometry
- liquid chromatography
- msms
- bile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides a method for quantitatively analyzing 15 bile acid substances in serum based on an LC-MSMS (liquid chromatography-mass spectrometry) technology, which belongs to the technical field of bile acid substance detection.
Description
Technical Field
The invention belongs to the technical field of bile acid substance detection, and particularly relates to a method for simultaneously and quantitatively analyzing 15 bile acid substances in serum based on an LC-MSMS (liquid chromatography-mass spectrometry) technology.
Background
Bile acid is an important component of bile, and can be divided into two major classes according to structure, wherein one class is free bile acid, including Cholic Acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA) and lithocholic acid (LCA); the other is combined bile acid, including glycoursodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), tauroursodeoxycholic acid (TUDCA), taurochenodeoxycholic acid (TCDCA), taurodeoxycholic acid (TDCA), glycocholic acid (GCA), taurocholic acid (TCA), glycolithocholic acid (GLCA), and taurocholic acid (TLCA). They play a key role in cholesterol and lipid metabolism and are important markers for clinically detecting whether liver and gallbladder function is normal or not.
In conventional clinical tests, total bile acid is generally determined using biochemical immunological techniques. Since bile acids with different structures have different physiological characteristics, accurate quantification of each bile acid becomes necessary, and the LC-MS/MS method has advantages over the conventional methods in terms of detection sensitivity, method specificity and the like. The prior art CN113009061A reports a method for detecting 15 bile acids by high performance liquid tandem mass spectrometry, which is unable to achieve complete separation of 15 compounds.
Disclosure of Invention
Based on the problems in the prior art, the invention provides a method for quantitatively analyzing 15 bile acid substances in serum based on an LC-MSMS (liquid chromatography-mass spectrometry) technology, which has the advantages of simple and rapid pretreatment steps, accurate detection, complete separation of 15 bile acids, convenience, rapidness and accuracy.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a method for the quantitative analysis of 15 bile acid substances in serum based on LC-MSMS technology, carry on the preliminary treatment of the tandem mass spectrometric detection of liquid chromatogram to the sample to be measured first, every sample after preliminary treatment carries on the tandem mass spectrometric detection of liquid chromatogram separately, 15 bile acid in the accurate quantitative analysis human blood composition at the same time; in the liquid chromatography tandem mass spectrometry detection, mass spectrometry adopts multi-reaction monitoring, and the MRM parameters of the compounds are as follows:
the mass spectrum is a triple quadrupole tandem mass spectrum.
According to the above scheme, the 15 kinds of bile acids are Cholic Acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), lithocholic acid (LCA), glycoursodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), tauroursodeoxycholic acid (TUDCA), tauroursodeoxycholic acid (TCDCA), tauroursodeoxycholic acid (TDCA), glycocholic acid (GCA), taurocholic acid (TCA), glycolithocholic acid (GLCA) and taurocholic acid (TLCA).
According to the scheme, the method for quantitatively analyzing the 15 bile acid substances in the serum based on the LC-MSMS technology comprises the following detailed steps:
step S1, preparing a calibrator solution, a quality control solution and an internal standard working solution with series concentrations;
step S2, adding internal standard working solution into the sample to be detected, and carrying out vortex mixing;
and step S3, centrifuging each sample mixed in the step S2, adding pure water into the supernatant after centrifugation, and performing LC-MS/MS analysis.
According to the above scheme, the conditions of the liquid chromatography are as follows:
and (3) analyzing the column: phenomenex Kinetex C18100A 2.6.6 μm,100x3 mm;
mobile phase: phase A: an aqueous solution containing 5mM ammonium acetate; phase B: 95% aqueous acetonitrile containing 5mM ammonium acetate;
elution gradient:
| time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 0.30 | 70 | 30 |
| 3.80 | 62 | 38 |
| 8.50 | 62 | 38 |
| 9.00 | 0 | 100 |
| 11.0 | 0 | 100 |
| 11.51 | 70 | 30 |
| 12 | 70 | 30 |
Flow rate: 0.4 mL/min; column temperature: at 40 ℃.
According to the above scheme, the mass spectrum conditions are as follows:
an ionization mode: spot spray ionization negative ion mode (ESI-); the detection mode is as follows: multiple Reaction Monitoring (MRM); ion source Temperature (TEM): 500 ℃; atomizing gas (GS 1): 50 psi; assist gas (GS 2): 50 psi; air curtain gas (CUR): 25 psi; electrospray voltage (IS): -4500V; collision gas (CAD): 8.
the invention has the beneficial effects that: the quantitative analysis method provided by the invention has the advantages of simple operation, short pretreatment time, and capability of realizing complete separation and accurate quantification of 15 bile acids.
Drawings
FIG. 1 is a diagram showing the results of liquid chromatography-tandem mass spectrometry analysis of lithocholic acid in the examples.
FIG. 2 is a diagram showing the results of liquid chromatography-tandem mass spectrometry analysis of chenodeoxycholic acid, deoxycholic acid and ursodeoxycholic acid in the examples.
FIG. 3 is a diagram showing the results of liquid chromatography-tandem mass spectrometry analysis of cholic acid in example.
FIG. 4 is a liquid chromatography-tandem mass spectrometry analysis result graph of glycolithocholic acid in the example.
FIG. 5 is a liquid chromatography-tandem mass spectrometry analysis result pattern of glycochenodeoxycholic acid, glycodeoxycholic acid, and glycoursodeoxycholic acid in the examples.
FIG. 6 is a liquid chromatography-tandem mass spectrometry analysis result graph of glycocholic acid in the example.
FIG. 7 is a diagram showing the results of liquid chromatography-tandem mass spectrometry analysis of taurocholic acid in examples.
FIG. 8 is a liquid chromatography-tandem mass spectrometry analysis result pattern of taurochenodeoxycholic acid, taurodeoxycholic acid, and tauroursodeoxycholic acid in examples.
FIG. 9 is a diagram showing the results of liquid chromatography-tandem mass spectrometry analysis of taurocholic acid in examples.
The figures are LC-MS/MS detection analysis result graphs which are result displays in the embodiment, characters in the graphs are result displays, and the results change according to the result of each detection analysis, namely the characters in the graphs are irrelevant to whether the detection method provided by the invention can be repeatedly implemented, and the characters in the graphs are unclear, so that a person skilled in the art can repeatedly implement the detection method provided by the invention.
Detailed Description
The technical solution of the present invention will be described below with reference to the specific embodiments and the accompanying drawings.
A method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology comprises the steps of carrying out pretreatment of liquid chromatography tandem mass spectrometry on samples to be detected, respectively carrying out liquid chromatography tandem mass spectrometry on each pretreated sample, and simultaneously accurately and quantitatively analyzing 15 bile acids in human blood components, wherein the 15 bile acids comprise Cholic Acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), lithocholic acid (LCA), glycodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TUDCA), taurodeoxycholic acid (TCDCA), taurocholic acid (TDCA), glycoursodeoxycholic acid (GCA), taurocholic acid (TCA), glycolithocholic acid (GLCA) and taurocholic acid (TLCA), and comprises the following detailed steps:
step S1, preparing a calibrator (standard) solution, a quality control solution and an internal standard working solution with series concentrations;
step S11, preparing a standard substance stock solution:
cholic Acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), lithocholic acid (LCA), glycoursodeoxycholic acid (GUDCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), tauroursodeoxycholic acid (TUDCA), tauroursodeoxycholic acid (TCDCA), tauroursodeoxycholic acid (TDCA), glycocholic acid (GCA), tauroursholic acid (TCA), glycolithocholic acid (GLCA) and tauroursodeoxycholic acid (TLCA) are respectively and accurately weighed and dissolved by pure methanol to obtain standard stock solutions with respective concentrations of 10 mM/L.
Step S12, preparing a standard substance mixed stock solution:
accurately transferring the standard substance stock solution of each compound prepared in the step S11 by using a pipettor, adding a pure methanol solution, uniformly mixing the standard substances of each bile acid, and preparing 15 kinds of mixed stock solutions of the standard substances of the bile acids, wherein the concentrations of chenodeoxycholic acid (CDCA), Cholic Acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA) and ursodeoxycholic acid (UDCA) are 500 mu M/L;
glycolithocholic acid (GLCA), lithocholic acid (LCA), taurolithocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA) concentration was 100. mu.M/L.
Step S13, preparing an internal standard stock solution:
accurately weighing glycoursodeoxycholic acid-D5 (GUDCA-D5), glycochenodeoxycholic acid-D7 (GCDCA-D7), glycodeoxycholic acid-D5 (GDCA-D5), tauroursodeoxycholic acid-D4 (TUDCA-D4), taurochenodeoxycholic acid-D5 (TCDCA-D5), taurodeoxycholic acid-D5 (TDCA-D5), ursodeoxycholic acid-D5 (UDCA-D5), chenodeoxycholic acid-D5 (CDCA-D5), deoxycholic acid-D5 (DCA-D5), glycocholic acid-D5 (GCA-D5), taurocholic acid-D5 (TCA-D5), cholic acid-D5 (CA-D5), glycocholic acid-D5 (GLCA-D5), lithocholic acid-D5) and taurocholic acid-D5 (TLCA-D5), and dissolved using pure methanol to give internal standard stock solutions each at a concentration of 5 mM/L.
Step S14, preparing standard curve working solution and quality control working solution:
standard curve working fluid: diluting the standard substance mixed stock solution in the step S12 with pure methanol to obtain a mixed standard substance working solution, wherein each point of the standard curve working solution has a concentration of 1 μ M/L, 2 μ M/L, 4 μ M/L, 10 μ M/L, 30 μ M/L, 60 μ M/L, 100 μ M/L and 200 μ M/L for chenodeoxycholic acid (CDCA), Cholic Acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA); glycolithocholic acid (GLCA), lithocholic acid (LCA), taurocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA) at each point concentration of 0.2. mu.M/L, 0.4. mu.M/L, 0.8. mu.M/L, 2. mu.M/L, 6. mu.M/L, 12. mu.M/L, 20. mu.M/L, 40. mu.M/L;
quality control working solution: diluting the standard substance mixed stock solution in the step S12 with pure methanol to obtain a quality control working solution, wherein each point of the quality control working solution has a concentration of 3 μ M/L, 50 μ M/L and 75 μ M/L, and the concentration of chenodeoxycholic acid (CDCA), Cholic Acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA) and ursodeoxycholic acid (UDCA);
concentrations of each point of Glycolithocholic acid (GLCA), lithocholic acid (LCA), taurocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA) were 0.6. mu.M/L, 10. mu.M/L, 15. mu.M/L.
Step S15, preparing internal standard working solution:
diluting the internal standard stock solution in the step S13 by using pure acetonitrile to obtain an internal standard working solution with the following concentration:
step S16, preparing a standard curve sample and a quality control product:
for the standard curve sample, 1% BSA was used as a substitute matrix, and the standard working solution obtained in step S14 was diluted by 20 times to obtain a standard curve sample, each point of which was 0.05 μ M/L, 0.1 μ M/L, 0.2 μ M/L, 0.5 μ M/L, 1.5 μ M/L, 3 μ M/L, 5 μ M/L, 10 μ M/L, chenodeoxycholic acid (CDCA), Cholic Acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), taurocholic acid (TCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA);
the concentrations of each point of the standard curves of glycolithocholic acid (GLCA), lithocholic acid (LCA), taurocholic acid (TLCA), and tauroursodeoxycholic acid (TUDCA) are 0.01. mu.M/L, 0.02. mu.M/L, 0.04. mu.M/L, 0.1. mu.M/L, 0.3. mu.M/L, 0.6. mu.M/L, 1. mu.M/L, and 2. mu.M/L.
For the quality control product, 20 human parts of mixed plasma prepared from human serum was divided into three parts as a substrate, and the quality control product was obtained by diluting the quality control working solution obtained in step S14 by 20 times, namely chenodeoxycholic acid (CDCA), Cholic Acid (CA), deoxycholic acid (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycoursodeoxycholic acid (GUDCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA), ursodeoxycholic acid (UDCA) at each point of 0.15 μ M/L, 2.5 μ M/L, 3.75 μ M/L.
Glycolithocholic acid (GLCA), lithocholic acid (LCA), taurocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA) each quality control point concentration is 0.03. mu.M/L, 0.5. mu.M/L, 0.75. mu.M/L.
Step S21, collecting a serum sample to be detected, taking at least 1mL of blood to be detected, after blood coagulation, centrifuging at 3000rpm for 15min, and separating to obtain supernatant serum, namely the serum sample to be detected;
and step S22, transferring 80 mu L of serum sample to be detected into a 96-well plate by using a pipette, adding 200 mu L of internal standard working solution, mixing and oscillating for 5 min.
And step S3, centrifuging each sample mixed in the step S22, each standard curve sample and the quality control product for 10min at 4000rpm, transferring 50 mu L of supernate to a new 96-well plate, adding 100 mu L of pure water for redissolving, and performing LC-MS/MS analysis.
The conditions of the liquid chromatography are as follows:
and (3) analyzing the column: phenomenex Kinetex C18100A 2.6.6 μm,100x3 mm;
mobile phase: phase A: an aqueous solution containing 5mM ammonium acetate; phase B: 95% aqueous acetonitrile containing 5mM ammonium acetate;
elution gradient:
| time (min) | Mobile phase A (%) | Mobile phase B (%) |
| 0.30 | 70 | 30 |
| 3.80 | 62 | 38 |
| 8.50 | 62 | 38 |
| 9.00 | 0 | 100 |
| 11.0 | 0 | 100 |
| 11.51 | 70 | 30 |
| 12 | 70 | 30 |
Flow rate: 0.4 mL/min; column temperature: at 40 ℃.
The mass spectrum conditions were as follows:
an ionization mode: spot spray ionization negative ion mode (ESI-); the detection mode is as follows: multiple Reaction Monitoring (MRM); ion source Temperature (TEM): 500 ℃; atomizing gas (GS 1): 50 psi; assist gas (GS 2): 50 psi; air curtain gas (CUR): 25 psi; electrospray voltage (IS): -4500V; collision gas (CAD): compound MRM parameters were as follows:
detecting the solution by high performance liquid chromatography triple quadrupole mass spectrometry, obtaining a standard curve equation by fitting peak area ratios of the standard substance and the internal standard substance as shown in figures 1-9, and calculating the concentration of the standard substance to be detected.
The present invention is provided by the above embodiments only for illustrating and not limiting the technical solutions of the present invention, and although the above embodiments describe the present invention in detail, those skilled in the art should understand that: modifications and equivalents may be made thereto without departing from the spirit and scope of the invention and any modifications and equivalents may fall within the scope of the claims.
Claims (5)
1. A method for quantitative analysis of 15 bile acid substances in serum based on LC-MSMS technology is characterized in that a sample to be detected is subjected to pretreatment of liquid chromatography tandem mass spectrometry, each pretreated sample is respectively subjected to liquid chromatography tandem mass spectrometry, and 15 bile acids in human blood components are accurately and quantitatively analyzed; in the liquid chromatography tandem mass spectrometry detection, mass spectrometry adopts multi-reaction monitoring, and the MRM parameters of the compounds are as follows:
the mass spectrum is a triple quadrupole tandem mass spectrum.
2. The method of claim 1, wherein the 15 bile acids are cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid, glycoursodeoxycholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid, tauroursodeoxycholic acid, taurodeoxycholic acid, glycocholic acid, taurocholic acid, glycolithocholic acid, and taurolithocholic acid.
3. The method for the quantitative analysis of 15 bile acid substances in the serum based on the LC-MSMS technology according to claim 2, which comprises the following detailed steps:
step S1, preparing a calibrator solution, a quality control solution and an internal standard working solution with series concentrations;
step S2, adding internal standard working solution into the sample to be detected, and carrying out vortex mixing;
and step S3, centrifuging each sample mixed in the step S2, adding pure water into the supernatant after centrifugation, and performing LC-MS/MS analysis.
4. The method for quantitative analysis of 15 bile acid substances in serum based on LC-MSMS technology according to claim 3, wherein the conditions of the liquid chromatography are as follows:
and (3) analyzing the column: phenomenex Kinetex C18100A 2.6.6 μm,100x3 mm;
mobile phase: phase A: an aqueous solution containing 5mM ammonium acetate; phase B: 95% aqueous acetonitrile containing 5mM ammonium acetate;
elution gradient:
Flow rate: 0.4 mL/min; column temperature: at 40 ℃.
5. The method of claim 4, wherein the mass spectrometry conditions are as follows:
an ionization mode: point spray ionization negative ion mode; the detection mode is as follows: monitoring multiple reactions; ion source temperature: 500 ℃; atomizing: 50 psi; auxiliary gas: 50 psi; air curtain air: 25 psi; electrospray voltage: -4500V; collision gas: 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111163684.3A CN113917016A (en) | 2021-09-30 | 2021-09-30 | Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111163684.3A CN113917016A (en) | 2021-09-30 | 2021-09-30 | Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113917016A true CN113917016A (en) | 2022-01-11 |
Family
ID=79237739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111163684.3A Pending CN113917016A (en) | 2021-09-30 | 2021-09-30 | Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113917016A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116183780A (en) * | 2023-04-25 | 2023-05-30 | 天津云检医学检验所有限公司 | Absolute quantitative analysis method for bile acid in serum sample |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109030676A (en) * | 2018-07-06 | 2018-12-18 | 易达精准（杭州）科技有限公司 | The tandem mass spectrum detection kit and its application of 16 kinds of bile acids are measured simultaneously |
| CN111257476A (en) * | 2020-03-17 | 2020-06-09 | 浙江迪赛思诊断技术有限公司 | Method for detecting 17 bile acids in serum by high performance liquid chromatography tandem mass spectrometry |
| CN111665308A (en) * | 2020-07-21 | 2020-09-15 | 南京品生医疗科技有限公司 | Kit for detecting 15 bile acids in serum and application thereof |
| CN111830161A (en) * | 2020-07-21 | 2020-10-27 | 南京品生医学检验实验室有限公司 | Method for detecting 15 bile acids in serum |
-
2021
- 2021-09-30 CN CN202111163684.3A patent/CN113917016A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109030676A (en) * | 2018-07-06 | 2018-12-18 | 易达精准（杭州）科技有限公司 | The tandem mass spectrum detection kit and its application of 16 kinds of bile acids are measured simultaneously |
| CN111257476A (en) * | 2020-03-17 | 2020-06-09 | 浙江迪赛思诊断技术有限公司 | Method for detecting 17 bile acids in serum by high performance liquid chromatography tandem mass spectrometry |
| CN111665308A (en) * | 2020-07-21 | 2020-09-15 | 南京品生医疗科技有限公司 | Kit for detecting 15 bile acids in serum and application thereof |
| CN111830161A (en) * | 2020-07-21 | 2020-10-27 | 南京品生医学检验实验室有限公司 | Method for detecting 15 bile acids in serum |
Non-Patent Citations (2)
| Title |
|---|
| 刘雅楠等: "HPLC-MS/MS 法同时测定大鼠血浆中26 种胆汁酸", 药物分析杂志 * |
| 陈冰婷等: "基于UPLC－MS/MS的2型糖尿病患者血清胆汁酸代谢产物分析", 分析测试学报 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116183780A (en) * | 2023-04-25 | 2023-05-30 | 天津云检医学检验所有限公司 | Absolute quantitative analysis method for bile acid in serum sample |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2826830C (en) | Methods and systems for determining the presence or amount of testosterone in a sample | |
| Matysik et al. | Quantification of steroid hormones in human serum by liquid chromatography-high resolution tandem mass spectrometry | |
| US8697450B2 (en) | Measuring levels of a metabolite | |
| CN111521705B (en) | Method for enriching bile acid in serum | |
| CN106680393B (en) | The method that Liquid Chromatography-Tandem Mass Spectrometry measures 14 kinds of Environmental Hormone contents in urine | |
| CN110927289A (en) | Steroid hormone detection kit | |
| CN111323507A (en) | Detection method for simultaneously detecting 11 steroids in serum based on solid phase extraction method | |
| CN112098532A (en) | Improved detection method for 15 bile acids in human serum by high performance liquid chromatography tandem mass spectrometry | |
| CN112986433A (en) | Method for detecting steroid content in human serum sample | |
| CN110824091A (en) | Steroid hormone detection method | |
| CN111307993A (en) | Method for detecting content of bile acid in blood | |
| CN111665308A (en) | Kit for detecting 15 bile acids in serum and application thereof | |
| US11536733B2 (en) | Methods and systems for the detection of 11-oxo androgens by LC-MS/MS | |
| CN113917016A (en) | Method for quantitatively analyzing 15 bile acid substances in serum based on LC-MSMS technology | |
| CN115963199A (en) | Quantitative detection method and application of steroid hormone in human/animal body fluid | |
| Song et al. | Quantitative MALDI-MS assay of steroid hormones in plasma based on hydroxylamine derivatization | |
| Field | Tandem mass spectrometry in hormone measurement | |
| CN109856266A (en) | Simultaneously in determination of the environment water sample a variety of trace salt sugar cortins analysis method | |
| CN115469035A (en) | Method for determining concentration of ursodeoxycholic acid and metabolite thereof in human plasma | |
| CN106680394A (en) | Kit for determining content of 14 environmental hormones in urine in liquid chromatography tandem mass spectrometry | |
| CN113533566A (en) | Method for rapidly determining content of 41 bile acids in serum based on LC-MS/MS method | |
| Petca et al. | Current trends of liquid chromatography tandem mass spectroscopy use in clinical gynecology | |
| CN116593628B (en) | LC-MS/MS-based method and kit for simultaneously detecting multiple steroid hormones in serum | |
| US20230128672A1 (en) | Methods and Systems for Measuring Progesterone Metabolites | |
| CN114487185B (en) | Separation and identification method of cholesterol pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |